AA amyloidosis is a protein misfolding disease characterized by extracellular deposition of amyloid A (AA) fibrils. AA amyloidosis has been identified in food animals, and it has been postulated that AA amyloidosis may be transmissible to different animal species. Since the precursor protein of AA fibrils is serum amyloid A (SAA), which is an inflammatory acute phase protein, AA amyloidosis is considered to be associated with inflammatory diseases such as rheumatoid arthritis. Chronic diseases such as autoimmune disease and type 2 diabetes mellitus could be potential factors for AA amyloidosis. In this study, to examine the relationship between the induction of AA amyloidosis and chromic abnormalities such as autoimmune disease or type 2 diabetes mellitus, amyloid fibrils from mice, cattle, or chickens were experimentally injected into disease model mice. Wild-type mice were used as controls. The concentrations of SAA, IL-6, and IL-10 in autoimmune disease model mice were higher than those of control mice. However, induction of AA amyloidosis in autoimmune disease and type 2 diabetes mellitus model mice was lower than that in control mice, and the amount of amyloid deposits in the spleens of both mouse models was lower than that of control mice according to Congo red staining and immunohistochemistry. These results suggest that factors other than SAA levels, such as an inflammatory or anti-inflammatory environment in the immune response, may be involved in amyloid deposition.
AA amyloidosis is a protein misfolding disease characterized by extracellular deposition of amyloid A (AA) fibrils. AA amyloidosis has been identified in food animals, and it has been postulated that AA amyloidosis may be transmissible to different animal species. Since the precursor protein of AA fibrils is serum amyloid A (SAA), which is an inflammatory acute phase protein, AA amyloidosis is considered to be associated with inflammatory diseases such as rheumatoid arthritis. Chronic diseases such as autoimmune disease and type 2 diabetes mellitus could be potential factors for AA amyloidosis. In this study, to examine the relationship between the induction of AA amyloidosis and chromic abnormalities such as autoimmune disease or type 2 diabetes mellitus, amyloid fibrils from mice, cattle, or chickens were experimentally injected into disease model mice. Wild-type mice were used as controls. The concentrations of SAA, IL-6, and IL-10 in autoimmune disease model mice were higher than those of control mice. However, induction of AA amyloidosis in autoimmune disease and type 2 diabetes mellitus model mice was lower than that in control mice, and the amount of amyloid deposits in the spleens of both mouse models was lower than that of control mice according to Congo red staining and immunohistochemistry. These results suggest that factors other than SAA levels, such as an inflammatory or anti-inflammatory environment in the immune response, may be involved in amyloid deposition.
Amyloid A (AA) amyloidosis is a protein misfolding disease characterized by the
extracellular deposition of insoluble amyloid fibrils with β-sheet-rich structures in
several organs, such as the spleen, liver, and kidney, that induces functional impairment
[12]. Amyloidosis is classified into approximately
30 types according to the precursor protein and clinical symptoms [28]. AA amyloidosis is a common form of fatal systemic amyloidosis. Since
the precursor protein of AA is serum amyloid A (SAA), which is an inflammatory acute phase
protein [8], AA amyloidosis is considered to be
associated with inflammatory diseases such as rheumatoid arthritis (RA) and familial
Mediterranean fever (FMF). SAA is primarily synthesized in the liver and increases by about
1,000-fold over normal levels in the plasma during the inflammatory acute-phase response
[26].In chronic inflammatory conditions such as RA and FMF, SAA can incidentally aggregate as
amyloid deposits in several organs, primarily in the spleen, liver, and kidney [32]. Indeed, a high incidence of AA amyloidosis among RApatients has been reported, and in Japan, 90% of AA amyloidosis cases in people occurs
secondary to RA [23]. Therefore, other inflammatory
diseases, such as other autoimmune diseases or type 2 diabetes mellitus, may be potential
factors for AA amyloidosis. In tissues of patients with autoimmune diseases, the deposition
of antibody-antigen immune complexes causes chronic inflammation [11]. In the blood of people with diabetes mellitus, SAA levels are
relatively high compared with those of healthy people [2].AA amyloidosis in mice can be experimentally induced by injection of AgNO3,
casein, or lipopolysaccharide as an inflammatory stimulant, which causes causes a
significant increase in SAA levels in the plasma, and the time to disease onset can be
markedly shortened by injection of amyloid fibrils extracted from amyloid-containing tissue
[19, 21].
Furthermore, possible transmission of AA amyloidosis from humans [27], mice [9, 31], cattle [4], fowls [10], and cheetahs [34] to mice has been reported. In addition, induction of AA amyloidosis in rabbits
using bovine amyloid fibrils has been reported [7,
20]. AA amyloid deposits have been observed in food
animals including slaughtered cattle [30, 33]. Therefore, it is considered that amyloid fibrils in
food animals such as cattle and chickens may have potential to induce AA amyloidosis in
humans with chronic disease.In this study, to investigate the relationship between the induction of AA amyloidosis and
chronic disease, amyloid fibrils were experimentally injected into two kinds of model mice,
C57BL lpr/lpr and C57BL Ham ob/ob mice. C57BL
lpr/lprmice are a model for autoimmune disease, which show systemic
autoimmunity [3], while C57BL Ham
ob/ob mice are a model for type 2 diabetes mellitus [2]. The transmission of AA amyloidosis was examined by
inoculation of murine, bovine, and chicken amyloid fibrils into both model mouse strains.
Our results revealed that the transmission of AA amyloidosis to these model mice occurred to
a lesser extent than in the controls, contrary to expectations.
Materials and Methods
Animals
Female C57BL lpr/lprmice, C57BL mice as a control for C57BL
lpr/lprmice, C57BL Ham ob/ob mice, and C57BL Ham+/+
mice as a control for C57BL Ham ob/ob mice were purchased from Japan SLC
(Shizuoka, Japan). C57BL lpr/lprmice are model animals for autoimmune
disease and show deposition of immune complexes in several organs that causes inflammation
[3]. C57BL lpr/lprmice were used
in experiments after confirming the development of systemic lupus erythematosus-like
disease by examining urine proteins using Albuwell M (Exocell, Philadelphia, PA, USA).
C57BL Ham ob/ob mice are model animals for type 2 diabetes mellitus
[2]. C57BL Ham ob/ob mice were
used in experiments after confirming the development of type 2 diabetes mellitus by
examining urinary glucose using a Glucose Colorimetric/Fluorometric Assay Kit (BioVision,
San Francisco, CA, USA). Animals were kept five mice per cage with ad
libitum access to feed and water. For adaptation to the laboratory environment,
animals were kept for four weeks before experiments. All procedures used in the following
experiments were approved by the Animal Care Committee at Gifu University (approval number
11104).
Extraction and purification of amyloid fibrils from murine, bovine, and chicken AA
amyloidosis
Amyloid fibrils were extracted from the spleens of AA amyloidosis-affected C57BL mice,
the livers of AA amyloidosis-affected cattle, and the livers of avian AA
amyloidosis-affected chickens, which were previously ascertained to have amyloid deposits
by Congo red staining and immunohistochemistry (IHC) as described in previous reports
[18, 22].
Extraction of AA fibrils was performed according to the method described by Pras
et al. [24]. Briefly, 2 g of the
spleens from mice or 8 g of the livers of cattle or chickens were homogenized in 80 ml of
0.15 M NaCl by a microhomogenizer (Microtec, Chiba, Japan) and centrifuged at 40,000 ×
g for 20 min at 4°C with an MLA-55 rotor using an Optima MAX-XP
ultracentrifuge (Beckman Coulter, Brea, CA, USA), and the supernatant was discarded. The
tissue pellet was suspended with 80 ml of 0.15 M NaCl and centrifuged again at 40,000 ×
g for 20 min at 4°C. This process was repeated five times. Then the
pellet was homogenized with 80 ml of distilled water and centrifuged again, and the
supernatant was collected. The pooled supernatants were centrifuged at 100,000 ×
g for 1 h at 4°C. Resulting pellets of amyloid fibrils were dissolved
in 8 ml of distilled water and stored at −30°C until use. The concentration of protein was
measured by a spectrophotometer (GeneQuant 100, GE Healthcare, Buckinghamshire, UK) using
a DC Protein Assay kit (Bio-Rad Laboratories, Hercules, CA, USA).
Coomassie Brilliant Blue staining and Western blot analysis of amyloid
fibrils
Amyloid fibrils were electrophoresed on 12% sodium dodecyl sulfatepolyacrylamide gels.
After electrophoresis, gels were stained with Coomassie Brilliant Blue (CBB). Another set
of electrophoresed gels was transferred onto PVDF membranes (Millipore, Billerica, MA,
USA) and blocked with 5% skim milk in phosphate buffered saline (PBS) supplemented with
0.1% Tween 20 (PBST). The membranes were incubated with anti-mouseSAA1goat antibody
(1:5,000) (AF2948, R&D Systems, Minneapolis, MN, USA), anti-bovineSAA1 monoclonal
antibody, 25BF12 (1:1,600) [29], which was purified
from the culture supernatant of hybridoma cells by protein A-sepharose (GE Healthcare), or
anti-chickenSAA1mouse antibody (1:1,600) [22] in
1% skim milk in PBST at room temperature for 1 h. Membranes were washed three times with
PBST and incubated with anti-goat IgG donkey antibody F (ab’)2 conjugated with
horseradish peroxidase (HRP) (1:1,000) (SC3851, Santa Cruz Biotechnology, Dallas, TX,
USA), anti-mouse IgG F (ab’)2 conjugated with HRP (1:1,600)
(NA9310V, GE Healthcare, Buckinghamshire, UK) in 1% skim milk in PBST at room temperature
for 45 min. The membranes were washed four times with PBST. The band of amyloid fibrils
was detected by an ECL Western Blotting Detection System (GE Healthcare), and bands in
Western blot analysis were visualized by an LAS 4000 mini (Fujifilm, Tokyo, Japan).
Induction of AA amyloidosis by injection with different amyloid fibrils and
AgNO3
As shown in Table 1, all mice in three experiments were sorted into four groups, with five mice
in each group according to inoculation with different amyloid fibrils at different doses.
Mice in the groups were injected with murine, bovine, or chicken amyloid fibrils by
intraperitoneal route. All mice were also injected subcutaneously with 0.5 ml of a 3%
solution of AgNO3. Before injection of amyloid fibrils, solutions containing
the fibrils were treated with three cycles of ultrasonication for 30 and quiescence of 1
min by an ultrasonic processor (model 7500, Seiko I&E, Tokyo, Japan). After
inoculation at 10 days, all mice were sacrificed, and then spleens, livers, kidneys,
lungs, hearts, and small intestines were collected, fixed in 10% neutral buffered
formalin, and embedded in paraffin.
Table 1.
Amyloid deposition in C57BL, C57BL lpr/lpr, C57BL Ham +/+, and
C57BL Ham ob/ob mice inoculated with several AA fibrils
Mice
Injection (+ 3% AgNO3)
Experiment 1
Experiment 2
Experiment 3
Age (weeks)
Injected amount of protein (μg)
Number of mice affected/examined
Age (weeks)
Injected amount of protein (μg)
Number of mice affected/examined
Age (weeks)
Injected amount of protein (μg)
Number of mice affected/examined
C57BL
Murine AA fibrils
18
300
5/5
21
300
5/5
NT
NT
NT
Bovine AA fibrils
300
0/5
300
0/5
Chicken AA fibrils
300
1/5
300
0/5
None
-
0/5
-
0/5
C57BL lpr/lpr
Murine AA fibrils
18
300
4/5
21
300
3/5
21
300
4/5
Bovine AA fibrils
300
0/10
300
0/5
1,500
0/5
Chicken AA fibrils
300
0/10
300
0/5
300
0/5
None
-
0/5
-
0/5
-
0/5
C57BL Ham +/+
Murine AA fibrils
18
300
5/5
30
300
5/5
NT
NT
NT
Bovine AA fibrils
300
0/5
1,500
2/5
Chicken AA fibrils
300
2/5
300
0/5
None
-
0/5
-
0/0
C57BL Ham ob/ob
Murine AA fibrils
18
300
5/5
30
300
4/5
NT
NT
NT
Bovine AA fibrils
300
0/5
1,500
0/5
Chicken AA fibrils
300
0/5
300
0/5
None
-
0/5
-
0/5
NT, not tested.
NT, not tested.
Detection of amyloid deposits and immunohistochemical examination
Deparaffinized tissue sections were stained with hematoxylin and eosin or Congo red
[25] and evaluated for amyloid depositions by a
polarized light microscope (BX43, Olympus, Tokyo, Japan). To confirm amyloid deposits,
sections with Congo red staining were checked for emerald-green birefringence under
polarized light. Another set of deparaffinized sections was processed for IHC using
steam/heat treatment by autoclave for antigen retrieval. The sections were washed with PBS
and treated with 3% H2O2 and then incubated with anti-mouseSAA1goat antibody (1:200) (AF2948, R&D Systems) as a primary antibody in PBS for 2 h at
37°C. The sections were incubated with SC3851 as a secondary antibody in PBS at room
temperature for 30 min, and color development with 3,3-diaminobenzidine-4HCl (DAB) was
performed for approximately 40s. Immunostained sections were observed with a BX43 light
microscope. The intensity of amyloid deposits was scored using the NIH ImageJ software
[1].
Measurement of concentrations of SAA and cytokines in serum
Blood samples were collected from mice by retro-orbital bleeding under inhalant
anesthesia before injection and 1 day after injection. Collected blood samples were
centrifuged at 7,000 × g for 10 min at 4°C in a TMA-29 rotor using an
MX-150 centrifuge (Tomy, Tokyo, Japan), and collected sera were stored at −30 °C until
use. Concentrations of SAA in sera were measured using a MouseSerum Amyloid A ELISA Kit
(Life Diagnostics, West Chester, PA, USA) according to the manufacturer’s instructions.
Concentrations of cytokines (interleukin 6 [IL-6] and IL-10) in sera were measured using a
mouse T helper type 1 (Th1)/Th2/Th17 cytokine cytometric bead array (CBA) kit (BD
Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer’s instructions. Data
were measured by a BD FACSCanto II flow cytometer (BD Biosciences) and analyzed with the
FACSDiva software (BD Biosciences).
Statistical analysis
Data were collected from at least three independent experiments, expressed as means ± SD,
and analyzed for statistical significance by unpaired t-test.
Results
Extraction and confirmation of amyloid fibrils from murine, bovine, and chicken
amyloidosis
Extracted murine, bovine, and chicken amyloid fibrils were examined by CBB staining and
Western blot analysis (Fig. 1). The molecular weights of the extracted amyloid fibrils were approximately 7–9
kDa, and the expected sized bands were detected by both CBB staining (Fig. 1, lanes 1, 3, 5, and 7) and Western blot analysis (Fig. 1, lanes 2, 4, 6, and 8). As AA amyloidosis
could not be induced by the first bovine amyloid fibrils in mice (Fig. 1, lanes 3 and 4), bovine amyloid fibrils were extracted again
(Fig. 1, lanes 5 and 6). The former bovine
amyloid fibrils (Fig. 1, lanes 3 and 4) were
injected into C57BL, C57BL lpr/lpr, C57BL Ham +/+, and C57BL Ham
ob/ob mice at 18 weeks in experiment 1 (Table 1). The latter bovine amyloid fibrils (Fig. 1, lanes 5 and 6) were injected into C57BL and
C57BL lpr/lprmice at 21 weeks in experiments 2 and 3 and into C57BL Ham
+/+ and C57BL Ham ob/ob mice at 30 weeks in experiment 2 (Table 1). Extractions of murine and chicken
amyloid fibrils were done once (Fig. 1, lanes 1,
2, 7, and 8), and the lots were used in all experiments.
Fig. 1.
Coomassie Brilliant Blue (CBB) staining and Western blot analysis of amyloid
fibrils extracted from the murine spleen, bovine liver, and chicken liver. A, murine
amyloid fibrils (1, 2); B, bovine amyloid fibrils (3, 4, 5, and 6); C, chicken
amyloid fibrils (7, 8). Amyloid fibrils with CBB staining (1, 3, 5, and 7) and
amyloid fibrils in Western blot analysis (2, 4, 6, and 8). Bovine amyloid fibrils
were extracted twice. The former were used in experiment 1, and the latter were used
in experiments 2 and 3.
Coomassie Brilliant Blue (CBB) staining and Western blot analysis of amyloid
fibrils extracted from the murine spleen, bovine liver, and chicken liver. A, murine
amyloid fibrils (1, 2); B, bovine amyloid fibrils (3, 4, 5, and 6); C, chicken
amyloid fibrils (7, 8). Amyloid fibrils with CBB staining (1, 3, 5, and 7) and
amyloid fibrils in Western blot analysis (2, 4, 6, and 8). Bovine amyloid fibrils
were extracted twice. The former were used in experiment 1, and the latter were used
in experiments 2 and 3.
Induction of AA amyloidosis by murine, bovine, and chicken amyloid fibrils
To investigate the induction of AA amyloidosis, mice were inoculated with
AgNO3 alone or with murine, bovine, or chicken amyloid fibrils with
AgNO3. C57BL lpr/lprmice and C57BL Ham
ob/ob mice were inoculated with AgNO3 and amyloid fibrils
after confirming that the level of urine protein or urine glucose was significantly higher
than that of control mice, respectively. The results of the C57BL mice and C57BL
lpr/lprmice groups in experiments 1, 2, and 3 are shown in Table 1. Murine AA fibrils caused AA amyloidosis
in all C57BL mice in experiments 1 and 2. In contrast, among C57BL
lpr/lprmice inoculated with murine amyloid fibrils, AA amyloidosis was
observed in 11 out of 15 mice in experiments 1, 2, and 3. Bovine AA fibrils did not cause
AA amyloidosis in either C57BL mice or C57BL lpr/lprmice in experiments
1, 2, or 3, even with 1,500 µg of bovine amyloid fibrils. Among C57BL
mice inoculated with chicken amyloid fibrils, AA amyloidosis was observed in 1 out of 10
mice in experiments 1 and 2. Injection of AgNO3 alone did not cause AA
amyloidosis in any C57BL mice or any C57BL lpr/lprmice (Table 1).The results of the C57BL Ham +/+ mice and C57BL Ham ob/ob mice groups in
experiments 1 and 2 are shown in Table 1.
Murine amyloid fibrils induced AA amyloidosis in all C57BL Ham +/+ mice. On the other
hand, among C57BL Ham ob/ob mice inoculated with murine amyloid fibrils,
9 out of 10 mice developed AA amyloidosis in experiments 1 and 2. Among C57BL Ham +/+ mice
inoculated with bovine amyloid fibrils, 2 out of 10 mice developed AA amyloidosis, but AA
amyloidosis was not observed in Ham ob/ob mice (Table 1). Among C57BL Ham +/+ mice inoculated with chicken
amyloid fibrils, 2 of the 10 mice developed AA amyloidosis in experiments 1 and 2, but no
AA amyloidosis was observed in C57BL Ham ob/ob mice. Injection of
AgNO3 alone did not cause AA amyloidosis in any C57BL Ham +/+ mice or any
C57BL Ham ob/ob mice (Table
1). The occurrence of AA amyloidosis in either the C57BL lpr/lpr
or C57BL Ham ob/ob mouse strain was not influenced by age.Amyloid deposits in murine spleens were examined by Congo red staining and IHC (Fig. 2). Amyloid deposits were seen around spleen follicles by staining with Congo red and
were also observed as green birefringence under polarized light in all groups (Fig. 2, upper panel). Moreover, these deposits
reacted with anti-mouseSAA antibody in IHC experiments, irrespective of the originating
species of amyloid fibrils used for induction of AA amyloidosis (Fig. 2, lower panel). Amyloid deposits were not observed in
kidneys, lungs, hearts, and small intestines.
Fig. 2.
Amyloid deposits in spleens of several mice. Amyloid deposits were stained with
Congo red and observed as green birefringence under polarized light. Amyloid fibrils
in spleens of 18-week-old mice (C57BL, C57BL lpr/lpr, C57BL Ham
+/+, and C57BL ob/ob) inoculated with murine amyloid fibrils were
reacted with AF2948 antibody in IHC. Also, amyloid fibrils in spleens of 18-and
30-week-old C57BL Ham +/+ mice inoculated with bovine amyloid fibrils and chicken
amyloid fibrils, respectively, were reacted with AF2948 antibody in IHC. Bar=100
µm.
Amyloid deposits in spleens of several mice. Amyloid deposits were stained with
Congo red and observed as green birefringence under polarized light. Amyloid fibrils
in spleens of 18-week-old mice (C57BL, C57BL lpr/lpr, C57BL Ham
+/+, and C57BL ob/ob) inoculated with murine amyloid fibrils were
reacted with AF2948 antibody in IHC. Also, amyloid fibrils in spleens of 18-and
30-week-old C57BL Ham +/+ mice inoculated with bovine amyloid fibrils and chicken
amyloid fibrils, respectively, were reacted with AF2948 antibody in IHC. Bar=100
µm.
Intensity scoring of amyloid deposits around spleen follicles
To estimate the severity of AA amyloidosis, the intensity of amyloid deposits around
spleen follicles from all samples was measured in IHC sections by using the ImageJ
software (Fig. 3). The respective scores of amyloid deposits in each tissues section of mice
inoculated with murine, chicken, or bovine amyloid fibrils are shown at the bottom of
Fig. 3.
Fig. 3.
Intensity scoring of amyloid deposits in the spleen using ImageJ. Amyloid fibrils
in spleens of mice inoculated with murine, bovine, or chicken amyloid fibrils were
reacted with AF2948 antibody in IHC. Images of IHC indicate amyloid deposits around
spleen follicles. ImageJ was used to measure the intensity of amyloid deposits.
ImageJ intensity scores are shown at the bottom. Bar=400 µm.
Intensity scoring of amyloid deposits in the spleen using ImageJ. Amyloid fibrils
in spleens of mice inoculated with murine, bovine, or chicken amyloid fibrils were
reacted with AF2948 antibody in IHC. Images of IHC indicate amyloid deposits around
spleen follicles. ImageJ was used to measure the intensity of amyloid deposits.
ImageJ intensity scores are shown at the bottom. Bar=400 µm.The relative mean values of ImageJ scores for the four groups of mice inoculated with
AgNO3 alone or murine amyloid fibrils, bovine amyloid fibrils, or chicken
amyloid fibrils with AgNO3 are shown in Fig.
4. The scores of C57BL lpr/lprmice inoculated with murine amyloid
fibrils were significantly lower than those of C57BL mice inoculated with murine amyloid
fibrils. The significant difference in the scores of amyloid deposits between C57BL
lpr/lpr and C57BL mice was statistically confirmed
(P<0.001) (Fig. 4).
Moreover, the ImageJ scores of C57BL Ham ob/ob mice inoculated with
murine AA fibrils were also significantly lower than those of C57BL Ham +/+ mice
inoculated with murine amyloid fibrils. The significant difference in the scores of
amyloid deposits between C57BL Ham ob/ob and C57BL Ham +/+ mice was
statistically confirmed (P=0.003) (Fig. 4). Amyloid deposits in groups inoculated with murine AA fibrils were more
severe than those in groups inoculated with bovine or chicken amyloid fibrils (Figs. 3 and
4).
Fig. 4.
Relative means of ImageJ intensity scores for amyloid deposits in spleens. Relative
ImageJ intensity scores of amyloid deposits were calculated from all mice inoculated
with amyloid fibril samples in each group. Mice were inoculated with
AgNO3, murine amyloid fibrils, bovine amyloid fibrils, or chicken
amyloid fibrils intraperitoneally and examined for amyloid deposits in spleens.
Results are expressed as means ± SD. **P<0.001 vs. C57BL.
*P<0.01 vs. C57BL Ham +/+.
Relative means of ImageJ intensity scores for amyloid deposits in spleens. Relative
ImageJ intensity scores of amyloid deposits were calculated from all mice inoculated
with amyloid fibril samples in each group. Mice were inoculated with
AgNO3, murine amyloid fibrils, bovine amyloid fibrils, or chicken
amyloid fibrils intraperitoneally and examined for amyloid deposits in spleens.
Results are expressed as means ± SD. **P<0.001 vs. C57BL.
*P<0.01 vs. C57BL Ham +/+.
Concentrations of SAA in serum
Concentrations of SAA were measured before injection and 1 day after injection of
AgNO3 and murine amyloid fibrils (Fig.
5). The concentrations of SAA in mice inoculated with bovine or chicken amyloid
fibrils with AgNO3 were the same as those in mice inoculated with murine
amyloid fibrils and AgNO3 (data not shown). At day 0, the relative
concentration of SAA in C57BL lpr/lprmice was significantly higher than
that in C57BL control mice, but the concentration of SAA in C57BL Ham
ob/ob mice at day 0 was the same as that in C57BL Ham +/+ mice. The
significant difference in SAA concentration between C57BL lpr/lprmice
and control mice was statistically confirmed (P=0.004) (Fig. 5). On the other hand, concentrations of SAA
were markedly raised at day 1 in response to inflammatory stimuli, but were the same in
all mice.
Fig. 5.
Concentrations of SAA in serum from different model mice inoculated with murine
amyloid fibrils.Concentrations of SAA in serum at days 0 and 1 were measured by
ELISA. Results are expressed as means ± SD. *P<0.01 vs.
C57BL.
Concentrations of SAA in serum from different model mice inoculated with murine
amyloid fibrils.Concentrations of SAA in serum at days 0 and 1 were measured by
ELISA. Results are expressed as means ± SD. *P<0.01 vs.
C57BL.
Concentrations of cytokines in serum
The relative concentrations of cytokines IL-6 and IL-10 were measured before injection
and 1 day after injection of AgNO3 and murine amyloid fibrils (Fig. 6). The concentrations of cytokines in mice inoculated with bovine or chicken amyloid
fibrils with AgNO3 were mostly the same as those in mice inoculated with murine
amyloid fibrils and AgNO3 (data not shown). The concentrations of IL-6 and
IL-10 in C57BL lpr/lprmice were significantly higher than those in C57BL
control mice at day 0, and the difference was statistically significant
(P<0.001) (Fig. 6A); in
particular, the concentration of IL-10 was 1,000 times that of control mice. On the other
hand, the concentrations of these cytokines were roughly the same in C57BL Ham +/+ mice
and C57BL Ham ob/ob mice at day 0 (Fig. 6B). The concentrations of IL-6 were raised at day 1 in response to
inflammatory stimuli in C57BL, C57BL lpr/lpr, C57BL Ham +/+, and C57BL
Ham ob/ob mice.
Fig. 6.
Concentrations of cytokines in serum from different model mice inoculated with
murine amyloid fibrils. Concentrations of IL-6 and IL-10 in serum at days 0 and 1
were measured with a CBA kit. Results are expressed as means ± SD.
**P<0.001 vs. C57BL.
Concentrations of cytokines in serum from different model mice inoculated with
murine amyloid fibrils. Concentrations of IL-6 and IL-10 in serum at days 0 and 1
were measured with a CBA kit. Results are expressed as means ± SD.
**P<0.001 vs. C57BL.
Discussion
Experimental induction of AA amyloidosis by murine, bovine, or chicken amyloid fibrils in
C57BL lpr/lprmice as a model for autoimmune disease occurred less often
than in control mice. In addition, the amount of amyloid deposits in autoimmune diseasemice
was less than that in control mice. Clinically, systemic AA amyloidosis has rarely been
described in patients with systemic lupus erythematosus (SLE) [6], which the C57BL lpr/lprmice were a model of in this
study. In contrast to SLE, patients with type 2 diabetes mellitus have a higher prevalence
of renal amyloidosis [5]. We used C57BL Ham
ob/ob mice as a type 2 diabetes mellitus model in this study. However,
experimental induction of AA amyloidosis in C57BL Ham ob/ob mice occurred
less often, and the amounts of amyloid deposits in them were less than those in control
mice. Therefore, AA amyloidosis was transmitted to two chronic diseasemouse models less
frequently than to control mice over the short experimental period. In practice, these
diseases progress over the course of long periods of time in patients and incidentally have
the potential for SAA elevation similar to that seen in acute infection. The elevation of
SAA spontaneously produces some small aggregation of SAA particles known as “seeds” that
play a role as templates for further SAA aggregation to form amyloid deposits [17]. However, the seeds may not have been sufficient in
these disease model mice over the short term of this study. In patients with these diseases,
the seeds may be formed by spontaneous aggregation of SAA through the rise and decline of
SAA levels over the long disease progression.Bovine and chicken amyloid fibrils showed different specificities with respect to the cause
of AA amyloidosis in mice and amyloid deposits in the spleen compared with murine amyloid
fibrils (Table 1 and Fig. 4), which is consistent with previous studies showing that it is
difficult to reproduce the transmission of AA amyloidosis between different animal species
[7, 19, 21, 24]. The
difference in specific cause of AA amyloidosis is probably due to the primary amino acid
structure of the SAA molecule [10]. Nucleotide and
amino acid identities between murineSAA and bovineSAA and between murineSAA and chickenSAA (GenBank accession nos.: mouse, NM_009117; bovine, XM_005226741; chicken, GU929209) are
estimated to be 78.3% and 68.6% (murine and bovine) and 60.4% and 61.2% (murine and
chicken), respectively.Since SAA is the precursor protein of amyloid fibrils [8], its high serum concentration is considered to be involved directly in the
induction of AA amyloidosis. Indeed, there is a report showing that suppression of SAA with
medication reduces amyloid deposits in patients with AA amyloidosis [16]. However, the amounts of amyloid deposits in C57BL
lpr/lprmice were markedly less than those in control mice, despite
higher starting serum concentrations of SAA in the former, contrary to expectations. In
addition, the amounts of amyloid deposits in C57BL Ham ob/ob mice were less
than those in control mice, although the concentrations of SAA were the same between them.
These results suggest that higher concentration of SAA is not the only factor that
determines incidence and intensity of amyloid deposits in mice. It has not yet been
explained why these model mice (C57BL lpr/lpr and C57BL Ham
ob/ob) are unsusceptible to the transmission of AA amyloidosis. However,
use of these model mice in the experimental transmission of AA amyloidosis might be a useful
approach to estimate the transmission and pathogenesis of AA amyloidosis between
animals.In this study, inflammatory stimuli increased IL-6 in the sera of all mice. IL-6 is a
proinflammatory cytokine that facilitates the production of SAA and has an important role in
amyloid deposition [15]. IL-10 is an
anti-inflammatory cytokine and inhibits the production of IL-6 [13], and it was found at high levels in C57BL lpr/lprmice in this study. The role of IL-10 in amyloid deposition remains unclear. However, it is
known that a proinflammatory or anti-inflammatory environment may modify the function of
macrophages in the formation or degradation of amyloids [14]. Thus, the anti-inflammatory environment in C57BL lpr/lprmice probably inhibited amyloid deposition.As described previously, AA amyloidosis is reported to be transmissible to different animal
species [19, 21]. If AA amyloidosis can be transmitted between different species, the presence
of AA amyloids in food animals might be a potential risk to public health. However, the
underlying pathogenic mechanism in AA amyloidosis and its prevention remain unclear [21]. Our findings demonstrate that inflammatory or
anti-inflammatory conditions are involved in amyloid deposition, in addition to the
concentration of SAA. Further investigations are necessary to identify the factors that
stimulate or inhibit the formation of amyloid deposits in disease model mice to further
understand the pathogenic mechanism of AA amyloidosis and its prevention.
Authors: B S Andrews; R A Eisenberg; A N Theofilopoulos; S Izui; C B Wilson; P J McConahey; E D Murphy; J B Roths; F J Dixon Journal: J Exp Med Date: 1978-11-01 Impact factor: 14.307